Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities.

Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195 Berlin, Germany.
Bioorganic & Medicinal Chemistry (Impact Factor: 2.9). 06/2003; 11(10):2163-74. DOI: 10.1016/S0968-0896(03)00120-2
Source: PubMed

ABSTRACT In this study, a novel series of imidazole-containing compounds with dual properties, that is, inhibitory potency at the enzyme histamine N(tau)-methyltransferase (HMT) and antagonist potency at histamine H(3) receptors was designed and synthesized. Pharmacologically, these new hybrid drugs were evaluated in functional assays for their inhibitory potencies at rat kidney HMT and for their antagonist activities on synaptosomes of rat cerebral cortex. For selected compounds, binding affinities at recombinant human histamine H(3) receptors were determined. The first compounds (1-10) of the series proved to be H(3) receptor ligands of high potency at rat synaptosomes or of high binding affinity at human H(3) receptors, respectively, but of only moderate activity as inhibitors of rat kidney HMT. In contrast, aminoquinoline- or tetrahydroacridine-containing derivatives 11-17 also displayed HMT inhibitory potency in the nanomolar concentration range. Preliminary data from molecular modeling investigations showed that the imidazole derivative 15 and the HMT inhibitor quinacrine possess identical binding areas. The most interesting compound (14) is simultaneously a highly potent H(3) receptor ligand (K(i)=4.1nM) and a highly potent HMT inhibitor (IC(50)=24nM), which makes this derivative a valuable pharmacological tool for further development.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive impairment is a dramatically increasing problem affecting many individuals as well as thehealth system. As we have no causal treatment for the loss of memory, symptomatic treatment isneeded. Influencing the ACh system is a generally accepted approach, although other therapeutictreatments are in various stages of development. The multiple target drug approach using hybridcompounds may be another optimized move forward for the treatment of cognitive disorders. Since thecomplex neuronal regulation is slowly being decoded, there is hope that ways will be found to stopneuronal loss and to generate new synapses.
    Journal of applied biomedicine 01/2007; · 0.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Quantitative Structure-Activity Relationships (QSAR) modeling tools play a critical role today in both drug design and environmental sciences. QSAR modeling seeks to discover and use mathematical relationships between molecular properties of the compounds (descriptors) and the often complex activity of interest. An extensive number of molecular descriptors exist which can and have been used to model a wide range of target activities. This complicates the task of selecting those that will be more suitable, especially when one tries to define an accurate, robust, predictive and (most importantly) interpretable model. Lately, recognition of the importance of the three-dimensionally (3D) structure and stereochemistry of molecules to their biological activity, and awareness of the limitations of classical approaches, led to many attempts to generate 3D descriptors either as a complement for 2D-QSAR models or for standalone 3D-QSAR models. This review describes the 3D descriptors available in the DRAGON software along with their successful applications primarily in Medicinal Chemistry, updating a previously published paper in Current Topics in Medicinal Chemistry (Helguera, A.M.; Combes, R.D.; González, M.P.; Cordeiro, M.N.D.S., 2008, 8, 1628-1655).
    01/2012: pages 119-193; , ISBN: 978-1-60805-4336
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The histamine H3 receptor (H3 R) is an important modulator of numerous central control mechanisms. Novel lead optimizations for H3 R antagonists/inverse agonists involved studies of structure-activity relationships, cross-affinities, and pharmacokinetic properties of promising ligands. Blockade of inhibitory histamine H3 autoreceptors reinforces histaminergic transmission, while antagonism of H3 heteroreceptors accelerates the corticolimbic liberation of acetylcholine, norepinephrine, glutamate, dopamine, serotonin and gamma-aminobutyric acid (GABA). The H3 R positioned at numerous neurotransmission crossroads indicates therapeutic applications of small-molecule H3 R modulators in a number of psychiatric and neurodegenerative diseases with various clinical candidates available. Dual target drugs displaying H3 R antagonism/inverse agonism with inhibition of acetylcholine esterase (AChE), histamine N-methyltransferase (HMT), or serotonin transporter (SERT) are novel class of procognitive agents. Main chemical diversities, pharmacophores, and pharmacological profiles of procognitive agents acting as H3 R antagonists/inverse agonists and dual H3 R antagonists/inverse agonists with inhibiting activity on AChE, HMT, or SERT are highlighted here.
    CNS Neuroscience & Therapeutics 05/2014; · 4.46 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014